Monday 21-11-2019

14:00-15:00  Lunch

15:00-20:00  Registration

16:00-17:00  CME Session 1: EAVA rising star 1
  Case Dialogue : High Risk Cases

Moderator: Elsayed Farag

Chairpersons (in alphabetical order)
Moheb Magdy
Ahmed Tag
Basem Abdelhameed
Tiamoor Mostafa
Ayman khairy

Panellists (in alphabetical order)
Abdalla Maghraby
Ahmed Naguib
Ahmed Yahia
Ashraf Alameen
Mohamed Samak

16:00-16:12  Case 1: Ain Shams Team
  Walid Sallam
  Moheb Morad

16:12-16:20  Discussion

16:20-16:32  Case 2: Zagazig Team
  Mohamed Mesbah
  Mohamed Samy

16:32-16:40  Discussion

16:40-16:52  Case 3
  Mostafa Dawood
  Mohamed Alaa

16:52-17:00  Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:05-17:50</td>
<td>CME 2: Game changing trial 1</td>
<td>Moderator: Tamer Moustafa</td>
</tr>
<tr>
<td></td>
<td>Chairpersons (in alphabetical order)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Abdel El Salam El Sherif</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Magdy Abdel Samie</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Magdy El Masry</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Magdy Matar</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ragab Abdel Salam</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reda Baioumy</td>
<td></td>
</tr>
<tr>
<td>17:05-17:17</td>
<td>Reduce It ....</td>
<td>Atef Elbahry.</td>
</tr>
<tr>
<td>17:17-17:20</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>17:20-17:32</td>
<td>Aspree</td>
<td>Sameh Salama.</td>
</tr>
<tr>
<td>17:32-17:35</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>17:35-17:47</td>
<td>Historic</td>
<td>Waleed Abdo.</td>
</tr>
<tr>
<td>17:47-17:50</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs</td>
<td></td>
</tr>
<tr>
<td>17:50-18:05</td>
<td>Management of dyslipidemia in diabetics: which patient and which goal</td>
<td>Ashraf Reda</td>
</tr>
<tr>
<td>18:05-18:10</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>18:10-18:25</td>
<td>When to treat hypertriglyceridemia</td>
<td>Tamer Moustafa</td>
</tr>
<tr>
<td>18:25-18:30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>18:30-18:45</td>
<td>Risk categories and treatment goals 2019</td>
<td>Atef Elbahry</td>
</tr>
<tr>
<td>18:45-18:50</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>18:50-19:15</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>19:15-20:50</td>
<td>CME 4: Pregnancy and the heart</td>
<td>Moderator: Mahmoud Soliman</td>
</tr>
<tr>
<td></td>
<td>Chairs</td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td>Dinner</td>
<td></td>
</tr>
</tbody>
</table>
EAVA Cardio Risk Conference
21-23 November 2019
Hurghada – Egypt

Thursday 21-11-2019

12:00 – 14:00 Registration

14:30-15:30 Lunch

15:35-16:29 Athero 1: Atherosclerosis Beyond Cholesterol

Moderator: Atef Elbahry

Chairs:
Ashraf Reda - Osama Sand - Ahmed Abdelaaty - Sanna Abdelshafy

15:35 – 15:50 Ceramide in Atherosclerosis

Atef Elbahry

15:50-15:53 Discussion

15:53-16:08 Serum Ceramide can be used to identify high risk patients

Rijo Laaksonen (Finland)

16:08-16:11 Discussion

16:11– 16:26 Sphingolipids in Atherosclerosis

Abdel Moniem Ibrahim

16:26-16:29 Discussion
# EAVA Cardio Risk Conference

**21-23 November 2019**  
Hurghada – Egypt

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:35 – 17:15</td>
<td>Game changing trial 2</td>
</tr>
</tbody>
</table>

Each presentation 12 min + 3 min discussion

**Moderator:** Tamer Moustafa

**Chairpersons (in alphabetical order)**

- Amr Zaki
- Bassem Zarif
- Hisham Salah
- Mahmoud Hassnaien
- Sameh Emil
- Tarek Naguib

**16:35-16:47**  
**Complete**  
Mohamed Sobhy

**16:47-16:50**  
**Discussion**

**16:50-17:02**  
**Ideal LM**  
Prof Adel El Atriby

**17:02-17:05**  
**Discussion**

**17:05-17:17**  
**Twilight**  
Amr El Hadidy

**17:17-17:20**  
**Discussion**

**17:20-17:45**  
**Session 2**

**Moderator:**

**Chairs:**
### Athero 2

Each presentation 15 minutes followed by 3 min. discussion

**Moderator:** Ashraf Reda

**Chairs:**

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:50</td>
<td>Gen therapy and dyslipidemia management</td>
<td>Peter Lansberg, Netherlands</td>
</tr>
<tr>
<td>17:50</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>18:05</td>
<td>Targeting ANGPLT3 for the treatment of dyslipidemia</td>
<td>G Norata, Italy</td>
</tr>
<tr>
<td>18:08</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>18:23</td>
<td>Thrombo- inflammation: the real targets</td>
<td>Andreas Zerlic, Austria</td>
</tr>
<tr>
<td>18:26</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>18:41</td>
<td>Cardiovascular outcomes of antidiabetic medications</td>
<td>Tamer Moustafa</td>
</tr>
<tr>
<td>18:45</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Coffee Break

**19:20 – 20:05** **Dialogue 1: Diabetes Mellitus**

**Moderator:** Ahmed Shawky

**Chairs:**

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:20</td>
<td>Cardiovascular outcomes of antidiabetic medications</td>
<td>Tamer Moustafa</td>
</tr>
<tr>
<td>19:20</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>19:35</td>
<td>Aspirin: to give or not to give in diabetics?</td>
<td>Yasser Huzayen</td>
</tr>
<tr>
<td>19:47</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>19:50</td>
<td>Coronary artery disease in diabetes</td>
<td>Ahmed Shawky</td>
</tr>
<tr>
<td>20:02</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
</tbody>
</table>
EAVA Cardio Risk Conference
21-23 November 2019
Hurghada – Egypt

20:10 - 20:55
Lipid 1 - PCSK9 SUMMIT : WHAT'S UP?

Each presentation 12 minutes followed by 3 min. discussion
MODERATOR: Atef Elbahry
CHAIR PERSONS:

20:10 – 20:22
PCSK9 Inhibitors & Real-World Evidence.
Atef Elbahry

20:22 - 20:25
Discussion

20:25 – 20:37
PCSK9-Targeted SI-RNA Therapy Inclisiran
Andreas Zirlik
Discussion

20:4 – 20:52
From Orion-1 to ORION-4 Studies What's Up?
Ihab Attia

20:52 - 20:55
Discussion

21:00
Dinner
EAVA Cardio Risk Conference
21-23 November 2019
Hurghada – Egypt

Friday 22-11-2019

12:00 – 14:00 Registration

14:00-15:00 Lunch

15:00-16:40 EAVA rising stars 2
Case Scenarios MCQs with Valuable Prizes

Moderator: Elsayed Farag - Mohamed Sadaka

Chairs:

Chairpersons (In alphabetical order)

Ahmed ELKersh
Ahmed Kamel
Ahmed Sabry
Mohamed Seleem
Mohamed Zahran
Waleed Ammar

15:00-15:10 Case 1 MCQs
Ahmed Bendary

15:10-15:20 Discussion

15:20-15:30 Case 2 MCQs
Sherif AbdelSamad

15:30-15:40 Discussion

15:40-15:50 Case 3 MCQs
Ahmed Shawky

15:50-16:00 Discussion

16:00-16:10 Case 4 MCQs
Kareem Mahmoud

16:10-16:20 Discussion

16:20-16:30 Case 5 MCQs
Mohamed Elfiky

16:30-16:40 Discussion
**16:45-17:30**  Lipid 2 - THE LDL-C AXIOMA

Each presentation 12 minutes followed by 3 min. discussion

**Moderator:** Atef Elbahry

**Chairpersons:**

- **Prognostic Value Of LDL-C Critical Difference Between Primary and Secondary Prevention.**
  Reijo Laaksonen (Finland)

  **Discussion**

- **LDL Lowering Or LDL Eradication What Should We Do?**
  Atef Elbahry

  **Discussion**

- **Risk Assessment of ASCVD Miss People Under Age Of 20ys And Above 79ys: Should It Be Revisited**
  Ashraf Reda

  **Discussion**

**17:35 – 18:15**  Game changing trial 3

Each presentation 12 min followed by 3 min discussion

**Moderator:** Tamer Moustafa

**Chairpersons (in alphabetical order)**

- Ali Saad
- Gamila Ismaiel
- Islam Shawky
- Mohamed Gamal
- Sameh Shaheen
- Tarek El Zawawy

**17:35-17:47**  DAPA HF

Hosam Hassan.

**17:47-17:50**  Discussion

**17:50-18:02**  New Ascend Omega 3

Ahmed Tag.

**18:02-18:05**  Discussion

**18:05-18:17**  Paragone HF

Hamza Kabil

**18:17-18:20**  Discussion
18:20-19:55  |  Joint 1 - EAVA and EAS joint session
Each presentation 15 min. followed by 5 min. for discussion

Moderators:
Alexandros Tselepis “ EAS”
Ashraf Reda “ EAVA”

Chairs: Atef Elbahry – Nabil Farag – Elsayed Farag

Introduction: Educational activities of EAS
Alexandros Tselepis – Greece.

Discussion

Lp (a) : Screening and approaches to management
Alexandros Tselpis - Greece

Discussion

Pharmacology of Bempedoic Acid
G Norata – Italy

Discussion

Remnant cholesterol and the residual risk
Ashraf Reda – Egypt

Discussion

19:55-20:30  |  Coffee Break

20:30-20:50  |  CME Session 5

Moderator
Chairs

20:50-21:10  |  Keynote Lecture

Chairs

Screening for Familial Hypercholesterolemia
Peter Lansberg Netherlands
21:10-21:55 Dialogue 2: Heart failure

Each presentation 12 min. Followed by 3 min discussion

Moderator: Ahmed Shawky
Chair:

21:10-21:22 Heart failure with preserved ejection fraction: pathophysiology and directions for management
Yasser Huzayen

21:22-21:25 Discussion

21:25-21:37 Heart failure in the era of SGLT2 inhibitors
Ahmed Shawky

21:37-21:40 Discussion

21:40-21:52 New medications in the pipeline
Elsayed Farag.

21:52-21:55 Discussion